Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Pathologic Complete Response 2Myelodysplastic Syndromes 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Leukemia 1Colorectal Neoplasms 1

Interventions

Nivolumab 2Counseling 2Bupropion 2Azacitidine 2venetoclax 1temsirolimus 1sargramostim 1pembrolizumab 1motexafin gadolinium 1mivebresib 1margetuximab 1entinostat 1cc-486 1Zinc Oxide 1Varenicline 1Tretinoin 1Topotecan 1Tobacco Use Cessation Devices 1Thalidomide 1TTI-621 1Specimen Handling 1Rituximab 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Paracentesis 1Nicotine Replacement Therapy 1Nicotine 1Monatide (IMS 3015) 1Metformin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Monatide (IMS 3015) × Other hematologic neoplasm × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡